Shenandoah’s portfolio of recombinant proteins is expected to complement Fujifilm Irvine Scientific’s advanced cell culture solutions and expertise in bioprocessing
Shenandoah manufactures recombinant proteins. (Credit: Michal Jarmoluk from Pixabay)
Fujifilm Corporation, through its subsidiary Fujifilm Irvine Scientific, is set to acquire US-based recombinant proteins manufacturer Shenandoah Biotechnology for an undisclosed sum.
Fujifilm Irvine Scientific is engaged in the development and production of serum-free and chemically defined cell culture media for life science research and bioproduction.
Shenandoah’s portfolio of recombinant proteins is expected to complement Fujifilm Irvine Scientific’s advanced cell culture solutions and expertise in bioprocessing.
Also, the acquisition is expected to help Fujifilm’s Life Sciences Business to achieve its sales target of JPY100bn (around $850m) by FY2025.
The transaction is anticipated to close later this month.
Fujifilm Corporation representative director, president and CEO Teiichi Goto said: “At Fujifilm, our goal has always been to bring new value to society through the creation of innovative technologies, products and services.
“The acquisition of Shenandoah Biotechnology marks an important milestone for us to establish a leading position as a partner for pharmaceutical customers in the rapidly-growing market of advanced therapy.
“Fujifilm will, by maximising our group synergy, continue to expand Life Sciences Business while contributing to the creation of new therapies that fulfil unmet medical needs.”
With the acquisition, the two companies will aim to address the life science research, discovery, and cell and gene therapy needs of customers.
Recently, Shenandoah rolled out its CTG Grade line of cytokines and growth factors, manufactured as per cGMP guidelines, at its new ISO 9001:2015 certified facility.
Shenandoah Biotechnology president Pamela De Lacy said: “At Shenandoah Biotechnology, our vision is to provide a superior and affordable source of recombinant proteins to the drug discovery, life science research, and cell and gene therapy markets.
“We are pleased to join Fujifilm Irvine Scientific given their experience with manufacturing ancillary materials for cell and gene therapy and commitment to providing high-quality products and service to customers.”
Earlier this year, Fujifilm signed an agreement with Atara Biotherapeutics to acquire the latter’s US cell therapy manufacturing facility, for $100m.